BUZZ-PREVIEW: Merck seen reporting Q2 EPS drop yr/yr, rev increase

Reuters07-29

BUZZ-PREVIEW: Merck seen reporting <a href="https://laohu8.com/S/QTWO">Q2</a> EPS drop yr/yr, rev increase

** Merck & Co MRK.N shares off ~0.6% on Mon ahead of Q2 financial report due before market open on Tues

** Wall Street on average expects Q2 adj EPS of $2.01 vs $2.28 in Q2 2024 on rev of $15.89 bln vs $ 16.11 bln in year-ago qtr, according to latest estimates gathered by LSEG

** In last 8 qtrs, MRK EPS and rev beat expectations every time

** Merck in Apr reported Q1 adj profit increase of 7% as lower costs helped offset a 2% decline in sales, reflecting a Jan decision to pause shipments of its Gardasil vaccine to China amid demand downturn

** MRK last traded at $84.25 vs median PT of $100, as per LSEG, which shows 27 analyst ratings: 6 'strong buy,' 10 'buy' and 11 'hold'

** YTD, shares down 15.3% vs decline of 1.9% for S&P 500 healthcare index .SPXHC and 5.2% gain for Dow Industrials .DJI

** MRK options imply a 4.9% swing for the shares, in either direction by Fri, per Trade Alert data; the stock has logged an avg move of 4.2% on the day of results over the last eight qtrs

(Reporting by Sinead Carew, Saqib Iqbal Ahmed)

((sinead.carew@thomsonreuters.com))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2555148706?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-07-29 03:11","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2555148706","market":"nz","top_or_hot":-1,"title":"BUZZ-PREVIEW: Merck seen reporting Q2 EPS drop yr/yr, rev increase","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-PREVIEW: Merck seen reporting <a href=\"https://laohu8.com/S/QTWO\">Q2</a> EPS drop yr/yr, rev increase</title></head><body><p>** Merck &amp; Co <span>MRK.N</span> shares off ~0.6% on Mon ahead of Q2 financial report due before market open on Tues</p><p>** <a href=\"https://laohu8.com/S/WSCO\">Wall Street</a> on average expects Q2 adj EPS of $2.01 vs $2.28 in Q2 2024 on rev of $15.89 bln vs $ 16.11 bln in year-ago qtr, according to latest estimates gathered by LSEG</p><p>** In last 8 qtrs, MRK EPS and rev beat expectations every time</p><p>** Merck in Apr reported<span> Q1 adj profit increase of 7%</span> as lower costs helped offset a 2% decline in sales, reflecting a Jan decision to pause shipments of its Gardasil vaccine to China amid demand downturn</p><p>** MRK last traded at $84.25 vs median PT of $100, as per LSEG, which shows 27 analyst ratings: 6 'strong buy,' 10 'buy' and 11 'hold'</p><p>** YTD, shares down 15.3% vs decline of 1.9% for S&amp;P 500 healthcare index <span>.SPXHC</span> and 5.2% gain for Dow Industrials <span>.DJI</span> </p><p>  ** MRK options imply a 4.9% swing for the shares, in either direction by Fri, per Trade Alert data; the stock has logged an avg move of 4.2% on the day of results over the last eight qtrs</p><p> (Reporting by Sinead Carew, Saqib Iqbal Ahmed)</p><p> ((sinead.carew@thomsonreuters.com))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BUZZ-PREVIEW: Merck seen reporting Q2 EPS drop yr/yr, rev increase</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBUZZ-PREVIEW: Merck seen reporting Q2 EPS drop yr/yr, rev increase\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-07-29 03:11</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-PREVIEW: Merck seen reporting <a href=\"https://laohu8.com/S/QTWO\">Q2</a> EPS drop yr/yr, rev increase</title></head><body><p>** Merck &amp; Co <span>MRK.N</span> shares off ~0.6% on Mon ahead of Q2 financial report due before market open on Tues</p><p>** <a href=\"https://laohu8.com/S/WSCO\">Wall Street</a> on average expects Q2 adj EPS of $2.01 vs $2.28 in Q2 2024 on rev of $15.89 bln vs $ 16.11 bln in year-ago qtr, according to latest estimates gathered by LSEG</p><p>** In last 8 qtrs, MRK EPS and rev beat expectations every time</p><p>** Merck in Apr reported<span> Q1 adj profit increase of 7%</span> as lower costs helped offset a 2% decline in sales, reflecting a Jan decision to pause shipments of its Gardasil vaccine to China amid demand downturn</p><p>** MRK last traded at $84.25 vs median PT of $100, as per LSEG, which shows 27 analyst ratings: 6 'strong buy,' 10 'buy' and 11 'hold'</p><p>** YTD, shares down 15.3% vs decline of 1.9% for S&amp;P 500 healthcare index <span>.SPXHC</span> and 5.2% gain for Dow Industrials <span>.DJI</span> </p><p>  ** MRK options imply a 4.9% swing for the shares, in either direction by Fri, per Trade Alert data; the stock has logged an avg move of 4.2% on the day of results over the last eight qtrs</p><p> (Reporting by Sinead Carew, Saqib Iqbal Ahmed)</p><p> ((sinead.carew@thomsonreuters.com))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"MRK","symbol_name":"默沙东","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250728:nL6N3TP0SD:1","article_id":"2555148706","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2555148706","pubTimestamp":1753729901,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BUZZ-PREVIEW: Merck seen reporting Q2 EPS drop yr/yr, rev increase** Merck & Co MRK.N shares off ~0.6% on Mon ahead of Q2 financial report due before market open on Tues** Wall Street on average expects Q2 adj EPS of $2.01 vs $2.28 in Q2 2024 on rev of $15.89 bln vs $ 16.11 bln in year-ago qtr, according to latest estimates gathered by LSEG** In last 8 qtrs, MRK EPS and rev beat expectations every time** Merck in Apr reported Q1 adj profit increase of 7% as lower costs helped offset a 2% decline in sales, reflecting a Jan decision to pause shipments of its Gardasil vaccine to China amid demand downturn** MRK last traded at $84.25 vs median PT of $100, as per LSEG, which shows 27 analyst ratings: 6 'strong buy,' 10 'buy' and 11 'hold'** YTD, shares down 15.3% vs decline of 1.9% for S&P 500 healthcare index .SPXHC and 5.2% gain for Dow Industrials .DJI   ** MRK options imply a 4.9% swing for the shares, in either direction by Fri, per Trade Alert data; the stock has logged an avg move of","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"MRK":"默沙东","IHE":"iShares U.S. Pharmaceuticals ETF"},"translate_title":"嗡嗡声预览：默克报告第二季度每股收益同比下降，营业额增加","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MRK":0.9,"IHE":0.9},"content_text":"BUZZ-PREVIEW: Merck seen reporting Q2 EPS drop yr/yr, rev increase** Merck & Co MRK.N shares off ~0.6% on Mon ahead of Q2 financial report due before market open on Tues** Wall Street on average expects Q2 adj EPS of $2.01 vs $2.28 in Q2 2024 on rev of $15.89 bln vs $ 16.11 bln in year-ago qtr, according to latest estimates gathered by LSEG** In last 8 qtrs, MRK EPS and rev beat expectations every time** Merck in Apr reported Q1 adj profit increase of 7% as lower costs helped offset a 2% decline in sales, reflecting a Jan decision to pause shipments of its Gardasil vaccine to China amid demand downturn** MRK last traded at $84.25 vs median PT of $100, as per LSEG, which shows 27 analyst ratings: 6 'strong buy,' 10 'buy' and 11 'hold'** YTD, shares down 15.3% vs decline of 1.9% for S&P 500 healthcare index .SPXHC and 5.2% gain for Dow Industrials .DJI   ** MRK options imply a 4.9% swing for the shares, in either direction by Fri, per Trade Alert data; the stock has logged an avg move of 4.2% on the day of results over the last eight qtrs (Reporting by Sinead Carew, Saqib Iqbal Ahmed) ((sinead.carew@thomsonreuters.com))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport,express","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2555148706","isCrawlerRequest":true}